Mr. Ciaran Murray is the Chief Executive Officer of ICON plc. He joined ICON as Chief Financial Officer in 2005 and served in that capacity until his appointment as Chief Executive Officer in 2011. Mr. Murray is an executive with 35 years of leadership experience forged from a career spent operating in global markets in high-growth entrepreneurial companies and blue-chip multi-nationals, including PricewaterhouseCoopers, Kraft Foods, Novell Inc., Northern Foods and Codec DSS. Mr. Murray has also played a leadership role in advocating for safe, ethical high-quality research through his 2014 Chairmanship of the Association of Clinical Research Organisations (ACRO). ACRO represents the CRO industry globally to key stakeholders including pharmaceutical, biotech and medical device companies, regulators, legislators and patient groups. In 2014, Mr. Murray was named as a leader in CRO Innovation by PharmaVOICE100, a listing of the most influential people in the biopharma industry. Mr. Murray graduated with a Bachelor of Commerce degree from University College Dublin and he is a Fellow of the Institute of Chartered Accountants in Ireland. Mr. Murray was awarded an Honorary Degree of Doctor of Laws from University College Dublin in 2013 for his support of third level research and innovation in Ireland.
Dr. Steve Cutler was appointed Chief Operating Officer of the Company in January 2014, having previously occupied the position of Group President, Clinical Research Services since November 2011. Dr. Cutler was appointed to the ICON Board of Directors in November 2015. Prior to joining the Company Dr. Cutler held the position of Chief Executive Officer of Kendle, having previously served as Chief Operating Officer. Prior to Kendle, Dr. Cutler spent 14 years with Quintiles where he served as Senior Vice President, Global Project Management; Senior Vice President, Clinical, Medical and Regulatory; Senior Vice President, Project Management - Europe; and Vice President, Oncology - Europe as well as regional leadership positions in South Africa and Australia. Prior to joining Quintiles, Dr. Cutler held positions with Sandoz (now Novartis) in Australia and Europe. Dr. Cutler holds a B.Sc. and a Ph.D from the University of Sydney and a Masters of Business Administration from the University of Birmingham (UK).
Mr. Brendan Brennan has served as Chief Financial Officer since February 2012. Mr. Brennan joined ICON in 2006 and he has served in a number of senior finance roles in the Company including the role of Senior Vice President of Corporate Finance. Prior to joining ICON, Mr. Brennan developed his corporate finance experience in Cement Roadstone Holdings, a major Irish building materials organization. Mr. Brennan qualified as a chartered accountant with PricewaterhouseCoopers and obtained a Bachelor’s degree in Accounting and Finance from Dublin City University.
Professor Buckley is ICON’s lead medical expert, representing the company’s position on key scientific, ethical and medical governance matters and he will also provide guidance and oversight to the medical and scientific groups across ICON. An endocrinologist with over 30 years’ experience, Professor Buckley joined ICON through the acquisition of Firecrest Clinical in 2011, where he was one of the founders of the company and Senior Vice President of Medical Affairs. Professor Buckley has extensive experience in clinical trials and chairs several independent Data and Safety Monitoring Boards for medium to large cardio-metabolic and rare disease clinical studies. Professor Buckley is Clinical Professor of Medicine and Pharmacology at the School of Medicine, University College Cork (UCC), Ireland, and has also been director of the university’s European Center for Clinical Trials in Rare Diseases. Professor Buckley has been a board member of the Irish Medicines Board and of the European Medical Agency (EMA)’s Scientific Advisory Group for Diabetes and Endocrinology since 2005. Professor Buckley was also a member of the EMA Committee for Orphan Medicinal Products from 2000-2003 and a member of the EMA’s panel of experts. Professor Buckley is also chairman of the Irish Statutory Anti-Doping Agency and is a member of the UK Anti-Doping Scientific Advisory Board.
Mr. Diarmaid Cunningham is Chief Administrative Officer, General Counsel, Executive Vice President and Company Secretary. Mr. Cunningham joined the Company in November 2009, appointed Company Secretary in October 2011 and appointed Chief Administrative Officer in July 2016. Mr. Cunningham spent 10 years with A&L Goodbody, one of Ireland's premier corporate law firms, prior to joining the Company. Mr. Cunningham graduated with a Bachelor of Business and Legal Studies from University College Dublin in 1997 and qualified as a lawyer with A&L Goodbody in 2001. In 2015, Mr. Cunningham completed the Stanford Executive Program at Stanford University in California. Mr. Cunningham served as Secretary to the Board of the Association of Clinical Research Organisations (ACRO) in 2013 and 2014. ACRO represents the CRO industry globally to key stakeholders including pharmaceutical, biotech and medical device companies, regulators, legislators and patient groups.
Mr. O'Leary is ICON's Chief Information officer previous to this he held the position of President of ICON Central Laboratories. Mr. O'Leary joined the company in Feb-2001 as Manager of Data management in Dublin, Mr. O'Leary subsequently went on to set-up ICON's process improvement initiative "IMPROVE" and returned to Data Management to become EU VP of Data Management before becoming Global Head of Data Management in 2006. From 1994-2001 Mr. O'Leary worked for SmithKline Beecham and later GlaxoSmithKline and held positions in Data Management, Project Management and resource Management. Mr. O'Leary is a graduate of Kingston University in Surrey and a Member of the Royal Society of Chemistry. Mr. O'Leary holds a Degree in Medicinal Chemistry and a Masters in Data Management.
In his role as Executive VP of Quality and Compliance, Dr. Neil McCullough provides strategic direction for quality management and quality assurance across all lines of business, ensuring full compliance with global regulations guiding the biopharmaceutical industry. Dr. McCullough brings to ICON over 22 years of leading quality functions for global pharmaceutical and clinical research organisations. Prior to ICON, Dr. McCullough led the global quality and compliance division of PPD, before which he spent nine years at Pfizer Inc. as a member of the Pfizer Global Medical Quality Assurance Leadership team. Prior to Pfizer, Dr. McCullough served as a quality consultant to GlaxoSmithKline's division of manufacturing. Dr. McCullough earned his doctorate in chemistry from the University of Kent at Canterbury in the UK and his masters in pharmaceutical medicine from Hibernia College, Dublin, in partnership with Harvard University and the Royal College of Physicians, Ireland.
Mr. Joe Cronin is the Executive Vice President of Human Resources, responsible for designing and implementing people practices and building organisational leadership and culture that enable ICON to execute its strategy. Mr. Cronin joined ICON in 2014. Mr. Cronin has almost 20 years of HR experience in a variety of global industries, including ten years at the Kellogg company in a number of regional and global HR leadership roles. Mr. Cronin also spent time early in his career with the General Motors (GM) Corporation and the Computer Sciences Corporation (CSC). Mr. Cronin has a Bachelor of Business degree with a major in Human Resources, from the University of Limerick.
Dr. Nuala Murphy has been President of ICON Clinical Services at ICON Plc since January 2014. Prior to this, Dr. Murphy served as Executive Vice President of clinical and data operations globally. Dr. Murphy has over 20 years’ experience within the pharmaceutical and CRO industry. Dr. Murphy joined ICON in 2012 from Quintiles where she led a clinical and data management workforce (since 2009).
Dr. Murphy also has over a decade of experience in therapeutics having led the CNS and internal medicine project management divisions for Quintiles. Dr. Murphy served in the field of late phase clinical research at Benefit International. During her tenure, Dr. Murphy published extensively in eminent peer reviewed journals. Having graduated from Trinity College Dublin, Dr. Murphy was awarded a PhD in neurochemistry, from the Department of Cardiovascular Studies in Leeds and conducted post-doctoral research in the Department of Neuropharmacology at the Collège de France in Paris.